40637h10 News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Gallacher Capital Management LLC boosted its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 85.2% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 11,403 shares of the biopharmaceutical company’s stock after acquiring an additional 5,245 shares during the period. […]

HC Wainwright restated their buy rating on shares of Halozyme Therapeutics (NASDAQ:HALO – Free Report) in a report issued on Tuesday, Benzinga reports. HC Wainwright currently has a $50.00 price target on the biopharmaceutical company’s stock. HALO has been the topic of a number of other reports. The Goldman Sachs Group dropped their price objective […]

Halozyme Therapeutics (NASDAQ:HALO – Get Free Report)‘s stock had its “buy” rating reaffirmed by equities research analysts at HC Wainwright in a research note issued on Tuesday, Benzinga reports. They presently have a $50.00 price target on the biopharmaceutical company’s stock. HC Wainwright’s price target would indicate a potential upside of 27.23% from the company’s […]

Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) – Investment analysts at Zacks Research lifted their FY2026 earnings per share estimates for Halozyme Therapeutics in a research report issued to clients and investors on Monday, April 22nd. Zacks Research analyst A. Chakraborty now forecasts that the biopharmaceutical company will post earnings of $5.16 per share for […]

HC Wainwright reissued their buy rating on shares of Halozyme Therapeutics (NASDAQ:HALO – Free Report) in a research note published on Wednesday morning, Benzinga reports. HC Wainwright currently has a $50.00 price objective on the biopharmaceutical company’s stock. A number of other research analysts have also weighed in on HALO. StockNews.com raised shares of Halozyme […]